Friday, November 27, 2020 9:50:07 AM
only fools would sell.
this stock--in terms of its true intrinsic value--is worth over $1 right now as far as biotechs go.
i mean they are simply huge. watch this incredible story unfold.
Bucillamine Phase 3 CoronaVirus interim results in December 2020
Smart Folks who like to see 1000%+ ROI are accumulating.
AstraZeneca’s ‘mistake’ in COVID-19 vaccine trials could halt approval
https://nypost.com/2020/11/26/astrazenecas-covid-19-vaccine-mistake-could-halt-approval/
$RVVTF
this stock--in terms of its true intrinsic value--is worth over $1 right now as far as biotechs go.
i mean they are simply huge. watch this incredible story unfold.
Bucillamine Phase 3 CoronaVirus interim results in December 2020
Smart Folks who like to see 1000%+ ROI are accumulating.
AstraZeneca’s ‘mistake’ in COVID-19 vaccine trials could halt approval
https://nypost.com/2020/11/26/astrazenecas-covid-19-vaccine-mistake-could-halt-approval/
$RVVTF
Recent RVVTF News
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
